These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19761931)

  • 1. Regadenoson: a new myocardial stress agent.
    Al Jaroudi W; Iskandrian AE
    J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regadenoson.
    Bengalorkar GM; Bhuvana K; Sarala N; Kumar TN
    J Postgrad Med; 2012; 58(2):140-6. PubMed ID: 22718059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
    Palani G; Ananthasubramaniam K
    Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
    Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L
    J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regadenoson (CV Therapeutics/Astellas).
    Eggbrecht H; Gössl M
    Curr Opin Investig Drugs; 2006 Mar; 7(3):264-71. PubMed ID: 16555687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regadenoson: a focused update.
    Ghimire G; Hage FG; Heo J; Iskandrian AE
    J Nucl Cardiol; 2013 Apr; 20(2):284-8. PubMed ID: 23229649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with regadenoson-induced ST-segment depression but normal perfusion on single-photon emission computed tomography.
    Uthamalingam S; Gurm GS; Ahmado I; Sidhu MS; Flynn J
    Angiology; 2013 Jan; 64(1):46-8. PubMed ID: 22323835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regadenoson in the detection of coronary artery disease.
    Buhr C; Gössl M; Erbel R; Eggebrecht H
    Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.
    Andrikopoulou E; Morgan CJ; Brice L; Bajaj NS; Doppalapudi H; Iskandrian AE; Hage FG
    J Nucl Cardiol; 2019 Apr; 26(2):616-628. PubMed ID: 29043556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.
    Gordi T; Blackburn B; Lieu H
    J Clin Pharmacol; 2007 Jul; 47(7):825-33. PubMed ID: 17585115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison.
    Cury RC; Kitt TM; Feaheny K; Akin J; George RT
    J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regadenoson stress for myocardial perfusion imaging.
    Reyes E
    Future Cardiol; 2016 Jan; 12(1):59-67. PubMed ID: 26639775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging.
    Andrikopoulou E; AlJaroudi WA; Farag A; Lester D; Patel H; Iskandrian AE; Hage FG
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1493-502. PubMed ID: 27079736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
    Arumugham P; Figueredo VM; Patel PB; Morris DL
    EuroIntervention; 2013 Feb; 8(10):1166-71. PubMed ID: 23164748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of pharmacologic stress: selective A2A adenosine receptor agonists.
    Cerqueira MD
    Am J Cardiol; 2004 Jul; 94(2A):33D-40D; discussion 40D-42D. PubMed ID: 15261132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.
    Hage FG; Perry G; Heo J; Iskandrian AE
    Am J Cardiol; 2010 Mar; 105(6):839-43. PubMed ID: 20211328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
    Iqbal FM; Hage FG; Ahmed A; Dean PJ; Raslan S; Heo J; Iskandrian AE
    JACC Cardiovasc Imaging; 2012 Oct; 5(10):1014-21. PubMed ID: 23058068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.